55 results
Search Results
2. The Bacterial Aspects of Dirty Money.
- Subjects
- *
PAPER money , *BACTERIAL contamination , *DUST , *HYGIENE , *DISEASE vectors - Abstract
The article focuses on the bacterial aspects of dirty money and the historical concern regarding the transmission of infectious material through currency. While previous worries highlighted the potential danger of dirty paper money, bacteriological investigations failed to find significant microbial distribution on paper currency, suggesting that the composition of printed bills might inhibit bacterial growth.
- Published
- 2024
- Full Text
- View/download PDF
3. How to Navigate the Pitfalls of AI Hype in Health Care.
- Author
-
Suran, Melissa and Hswen, Yulin
- Subjects
DATA privacy ,ARTIFICIAL intelligence ,MEDICAL care ,COMPUTER science ,COLLEGE teachers - Abstract
In this Medical News article, Arvind Narayanan, PhD, a professor of computer science at Princeton University, discusses the benefits of using artificial intelligence in research and clinical settings while remaining cautious of hype, biases, and data privacy issues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Aftermath.
- Author
-
Nigliazzo, Stacy R.
- Subjects
MEDICAL periodicals ,MEDICAL societies - Abstract
The poem "Aftermath" by Stacy R. Nigliazzo is presented. First line: Asters reach from paper cups across the nurses' desk. ; Last Line: Some of us cry. All of us get back to work.
- Published
- 2024
- Full Text
- View/download PDF
5. Blind Spots, Shortcuts, and Automation Bias—Researchers Are Aiming to Improve AI Clinical Models.
- Author
-
Abbasi, Jennifer and Hswen, Yulin
- Subjects
RESEARCH personnel ,ARTIFICIAL intelligence ,AUTOMATION ,COMPUTER scientists - Abstract
This Medical News article is an interview with University of Michigan computer scientist Jenna Wiens, whose research interests lie at the intersection of AI and health care, and JAMA Editor in Chief Kirsten Bibbins-Domingo. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Waiting Room.
- Author
-
Stein, Gary
- Subjects
WAITING rooms ,MEDICAL periodicals - Abstract
The poem "Waiting Room" by Gary Stein is presented. First Line: Others have come and gone. Last Line: to receive your future.
- Published
- 2024
- Full Text
- View/download PDF
7. Risk Assessment and Prevention of Falls in Older Community-Dwelling Adults: A Review.
- Author
-
Colón-Emeric, Cathleen S., McDermott, Cara L., Lee, Deborah S., and Berry, Sarah D.
- Subjects
OLDER people ,LEG exercises ,ACCIDENTAL fall prevention ,ORTHOSTATIC hypotension ,ADULTS ,LEG pain ,RISK assessment ,EXERCISE therapy - Abstract
This Review summarizes current best practices for risk stratification, clinical assessment, and selection of risk reduction interventions for falls in community-dwelling older adults. Importance: Falls are reported by more than 14 million US adults aged 65 years or older annually and can result in substantial morbidity, mortality, and health care expenditures. Observations: Falls result from age-related physiologic changes compounded by multiple intrinsic and extrinsic risk factors. Major modifiable risk factors among community-dwelling older adults include gait and balance disorders, orthostatic hypotension, sensory impairment, medications, and environmental hazards. Guidelines recommend that individuals who report a fall in the prior year, have concerns about falling, or have gait speed less than 0.8 to 1 m/s should receive fall prevention interventions. In a meta-analysis of 59 randomized clinical trials (RCTs) in average-risk to high-risk populations, exercise interventions to reduce falls were associated with 655 falls per 1000 patient-years in intervention groups vs 850 falls per 1000 patient-years in nonexercise control groups (rate ratio [RR] for falls, 0.77; 95% CI, 0.71-0.83; risk ratio for number of people who fall, 0.85; 95% CI, 0.81-0.89; risk difference, 7.2%; 95% CI, 5.2%-9.1%), with most trials assessing balance and functional exercises. In a meta-analysis of 43 RCTs of interventions that systematically assessed and addressed multiple risk factors among individuals at high risk, multifactorial interventions were associated with 1784 falls per 1000 patient-years in intervention groups vs 2317 falls per 1000 patient-years in control groups (RR, 0.77; 95% CI, 0.67-0.87) without a significant difference in the number of individuals who fell. Other interventions associated with decreased falls in meta-analysis of RCTs and quasi-randomized trials include surgery to remove cataracts (8 studies with 1834 patients; risk ratio [RR], 0.68; 95% CI, 0.48-0.96), multicomponent podiatry interventions (3 studies with 1358 patients; RR, 0.77; 95% CI, 0.61-0.99), and environmental modifications for individuals at high risk (12 studies with 5293 patients; RR, 0.74; 95% CI, 0.61-0.91). Meta-analysis of RCTs of programs to stop medications associated with falls have not found a significant reduction, although deprescribing is a component of many successful multifactorial interventions. Conclusions and Relevance: More than 25% of older adults fall each year, and falls are the leading cause of injury-related death in persons aged 65 years or older. Functional exercises to improve leg strength and balance are recommended for fall prevention in average-risk to high-risk populations. Multifactorial risk reduction based on a systematic clinical assessment for modifiable risk factors may reduce fall rates among those at high risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Integrated Hepatitis C–Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial.
- Author
-
Talal, Andrew H., Markatou, Marianthi, Liu, Anran, Perumalswami, Ponni V., Dinani, Amreen M., Tobin, Jonathan N., and Brown, Lawrence S.
- Subjects
HEPATITIS C ,MEDICAL care ,DRUG abuse treatment ,DRUG abuse ,HEPATITIS C virus ,OPIOID abuse ,CLUSTER randomized controlled trials - Abstract
Key Points: Question: Among people receiving care in opioid treatment programs, does facilitated telemedicine for hepatitis C treatment increase cure rates compared with standard-of-care referral to hepatitis specialists? Findings: Cure percentages were 90.2% in telemedicine and 39.4% in referral, with an estimated logarithmic odds ratio of the study group effect of 2.9. Among cured participants, illicit drug use decreased significantly. We observed minimal reinfections during 2 years of follow-up. Meaning: Facilitated telemedicine integrated into opioid treatment programs resulted in significantly higher cure rates, with significant reductions in illicit drug use and minimal reinfections; facilitated telemedicine increases hepatitis C treatment access for underserved populations. Importance: Facilitated telemedicine may promote hepatitis C virus elimination by mitigating geographic and temporal barriers. Objective: To compare sustained virologic responses for hepatitis C virus among persons with opioid use disorder treated through facilitated telemedicine integrated into opioid treatment programs compared with off-site hepatitis specialist referral. Design, Setting, and Participants: Prospective, cluster randomized clinical trial using a stepped wedge design. Twelve programs throughout New York State included hepatitis C–infected participants (n = 602) enrolled between March 1, 2017, and February 29, 2020. Data were analyzed from December 1, 2022, through September 1, 2023. Intervention: Hepatitis C treatment with direct-acting antivirals through comanagement with a hepatitis specialist either through facilitated telemedicine integrated into opioid treatment programs (n = 290) or standard-of-care off-site referral (n = 312). Main Outcomes and Measures: The primary outcome was hepatitis C virus cure. Twelve programs began with off-site referral, and every 9 months, 4 randomly selected sites transitioned to facilitated telemedicine during 3 steps without participant crossover. Participants completed 2-year follow-up for reinfection assessment. Inclusion criteria required 6-month enrollment in opioid treatment and insurance coverage of hepatitis C medications. Generalized linear mixed-effects models were used to test for the intervention effect, adjusted for time, clustering, and effect modification in individual-based intention-to-treat analysis. Results: Among 602 participants, 369 were male (61.3%); 296 (49.2%) were American Indian or Alaska Native, Asian, Black or African American, multiracial, or other (ie, no race category was selected, with race data collected according to the 5 standard National Institutes of Health categories); and 306 (50.8%) were White. The mean (SD) age of the enrolled participants in the telemedicine group was 47.1 (13.1) years; that of the referral group was 48.9 (12.8) years. In telemedicine, 268 of 290 participants (92.4%) initiated treatment compared with 126 of 312 participants (40.4%) in referral. Intention-to-treat cure percentages were 90.3% (262 of 290) in telemedicine and 39.4% (123 of 312) in referral, with an estimated logarithmic odds ratio of the study group effect of 2.9 (95% CI, 2.0-3.5; P <.001) with no effect modification. Observed cure percentages were 246 of 290 participants (84.8%) in telemedicine vs 106 of 312 participants (34.0%) in referral. Subgroup effects were not significant, including fibrosis stage, urban or rural participant residence location, or mental health (anxiety or depression) comorbid conditions. Illicit drug use decreased significantly (referral: 95% CI, 1.2-4.8; P =.001; telemedicine: 95% CI, 0.3-1.0; P <.001) among cured participants. Minimal reinfections (n = 13) occurred, with hepatitis C virus reinfection incidence of 2.5 per 100 person-years. Participants in both groups rated health care delivery satisfaction as high or very high. Conclusions and Relevance: Opioid treatment program–integrated facilitated telemedicine resulted in significantly higher hepatitis C virus cure rates compared with off-site referral, with high participant satisfaction. Illicit drug use declined significantly among cured participants with minimal reinfections. Trial Registration: ClinicalTrials.gov Identifier: NCT02933970 This study discusses whether facilitated telemedicine for hepatitis C treatment increases cure rates compared with standard-of-care referral to hepatitis specialists. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Arteriovenous Access for Hemodialysis: A Review.
- Author
-
Lok, Charmaine E., Huber, Thomas S., Orchanian-Cheff, Ani, and Rajan, Dheeraj K.
- Subjects
RENAL replacement therapy ,HEMODIALYSIS ,ARTERIAL catheterization ,CHRONIC kidney failure ,ARTERIOVENOUS fistula - Abstract
Importance: Hemodialysis requires reliable vascular access to the patient's blood circulation, such as an arteriovenous access in the form of an autogenous arteriovenous fistula or nonautogenous arteriovenous graft. This Review addresses key issues associated with the construction and maintenance of hemodialysis arteriovenous access. Observations: All patients with kidney failure should have an individualized strategy (known as Patient Life-Plan, Access Needs, or PLAN) for kidney replacement therapy and dialysis access, including contingency plans for access failure. Patients should be referred for hemodialysis access when their estimated glomerular filtration rate progressively decreases to 15 to 20 mL/min, or when their peritoneal dialysis, kidney transplant, or current vascular access is failing. Patients with chronic kidney disease should limit or avoid vascular procedures that may complicate future arteriovenous access, such as antecubital venipuncture or peripheral insertion of central catheters. Autogenous arteriovenous fistulas require 3 to 6 months to mature, whereas standard arteriovenous grafts can be used 2 to 4 weeks after being established, and "early-cannulation" grafts can be used within 24 to 72 hours of creation. The prime pathologic lesion of flow-related complications of arteriovenous access is intimal hyperplasia within the arteriovenous access that can lead to stenosis, maturation failure (33%-62% at 6 months), or poor patency (60%-63% at 2 years) and suboptimal dialysis. Nonflow complications such as access-related hand ischemia ("steal syndrome"; 1%-8% of patients) and arteriovenous access infection require timely identification and treatment. An arteriovenous access at high risk of hemorrhaging is a surgical emergency. Conclusions and Relevance: The selection, creation, and maintenance of arteriovenous access for hemodialysis vascular access is critical for patients with kidney failure. Generalist clinicians play an important role in protecting current and future arteriovenous access; identifying arteriovenous access complications such as infection, steal syndrome, and high-output cardiac failure; and making timely referrals to facilitate arteriovenous access creation and treatment of arteriovenous access complications. This Review discusses the selection, creation, and maintenance of arteriovenous access for hemodialysis for patients with kidney failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Individualized Treatment Effects of Oxygen Targets in Mechanically Ventilated Critically Ill Adults.
- Author
-
Buell, Kevin G., Spicer, Alexandra B., Casey, Jonathan D., Seitz, Kevin P., Qian, Edward T., Graham Linck, Emma J., Self, Wesley H., Rice, Todd W., Sinha, Pratik, Young, Paul J., Semler, Matthew W., and Churpek, Matthew M.
- Subjects
MACHINE learning ,ARTIFICIAL respiration ,CRITICALLY ill ,ADULTS ,INTENSIVE care units - Abstract
Key Points: Question: Among critically ill adults, do the effects of peripheral oxygen-saturation (Spo
2 ) targets on outcomes differ based on an individual's characteristics? Findings: A machine learning model derived in one randomized trial and validated in another found that the predicted effect of lower vs higher Spo2 targets ranged from a 27% absolute reduction to a 34% absolute increase in 28-day mortality and differed significantly based on an individual's characteristics. Meaning: The effect of oxygen-saturation targets on mortality varied by patients' individual characteristics. Importance: Among critically ill adults, randomized trials have not found oxygenation targets to affect outcomes overall. Whether the effects of oxygenation targets differ based on an individual's characteristics is unknown. Objective: To determine whether an individual's characteristics modify the effect of lower vs higher peripheral oxygenation-saturation (Spo2 ) targets on mortality. Design, Setting, and Participants: A machine learning model to predict the effect of treatment with a lower vs higher Spo2 target on mortality for individual patients was derived in the Pragmatic Investigation of Optimal Oxygen Targets (PILOT) trial and externally validated in the Intensive Care Unit Randomized Trial Comparing Two Approaches to Oxygen Therapy (ICU-ROX) trial. Critically ill adults received invasive mechanical ventilation in an intensive care unit (ICU) in the United States between July 2018 and August 2021 for PILOT (n = 1682) and in 21 ICUs in Australia and New Zealand between September 2015 and May 2018 for ICU-ROX (n = 965). Exposures: Randomization to a lower vs higher Spo2 target group. Main Outcome and Measure: 28-Day mortality. Results: In the ICU-ROX validation cohort, the predicted effect of treatment with a lower vs higher Spo2 target for individual patients ranged from a 27.2% absolute reduction to a 34.4% absolute increase in 28-day mortality. For example, patients predicted to benefit from a lower Spo2 target had a higher prevalence of acute brain injury, whereas patients predicted to benefit from a higher Spo2 target had a higher prevalence of sepsis and abnormally elevated vital signs. Patients predicted to benefit from a lower Spo2 target experienced lower mortality when randomized to the lower Spo2 group, whereas patients predicted to benefit from a higher Spo2 target experienced lower mortality when randomized to the higher Spo2 group (likelihood ratio test for effect modification P =.02). The use of a Spo2 target predicted to be best for each patient, instead of the randomized Spo2 target, would have reduced the absolute overall mortality by 6.4% (95% CI, 1.9%-10.9%). Conclusion and relevance: Oxygenation targets that are individualized using machine learning analyses of randomized trials may reduce mortality for critically ill adults. A prospective trial evaluating the use of individualized oxygenation targets is needed. This cohort study examines whether peripheral oxygenation-saturation targets on mortality would differ by individual patient characteristics among 2 temporally and geographically distinct randomized trials of lower vs higher Spo2 targets in critically ill patients receiving mechanical ventilation [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
11. 2023 Year in Review and What's Ahead at JAMA.
- Author
-
Bibbins-Domingo, Kirsten, Flanagin, Annette, Christiansen, Stacy, Park, Hannah, and Curfman, Greg
- Subjects
PATIENT portals ,SURGICAL site infections - Abstract
The article focuses on the periodical's achievements and initiatives in 2023. It highlighting key metrics; new initiatives like JAMA Express for timely publication of high-importance manuscripts; the diverse range of content published to cater to global readership interests, including Alzheimer's research, COVID-19 studies and discussions on artificial intelligence in medicine; and fellowship programs and partnerships with academic institutions.
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical, Biomarker, and Research Tests Among US Government Personnel and Their Family Members Involved in Anomalous Health Incidents.
- Author
-
Chan, Leighton, Hallett, Mark, Zalewski, Chris K., Brewer, Carmen C., Zampieri, Cris, Hoa, Michael, Lippa, Sara M., Fitzgibbon, Edmond, French, Louis M., Moses, Anita D., van der Merwe, André J., Pierpaoli, Carlo, Turtzo, L. Christine, Yonter, Simge, Shahim, Pashtun, Moore, Brian, Stamps, Lauren, Flynn, Spencer, Fontana, Julia, and Tata, Swathi
- Subjects
POST-traumatic stress ,GLIAL fibrillary acidic protein ,POST-traumatic stress disorder ,SOUND pressure ,FATIGUE (Physiology) ,NEUROLOGICAL disorders - Abstract
Key Points: Questions: Do US government officials and their family members involved in anomalous health incidents (AHIs) differ from control participants with respect to clinical, biomarker, and research assessments? Findings: In this exploratory study that included 86 participants reporting AHIs and 30 vocationally matched control participants, there were no significant differences in most tests of auditory, vestibular, cognitive, visual function, or blood biomarkers between the groups. Participants with AHIs performed significantly worse on self-reported and objective measures of balance, and had significantly increased symptoms of fatigue, posttraumatic stress disorder, and depression compared with the control participants; 24 participants (28%) with AHIs presented with functional neurological disorders. Meaning: In this exploratory study, there were no significant differences between individuals reporting AHIs and matched control participants with respect to most clinical, research, and biomarker measures, except for self-reported and objective measures of imbalance; symptoms of fatigue, posttraumatic stress, and depression; and the development of functional neurological disorders in some. Importance: Since 2015, US government and related personnel have reported dizziness, pain, visual problems, and cognitive dysfunction after experiencing intrusive sounds and head pressure. The US government has labeled these anomalous health incidents (AHIs). Objective: To assess whether participants with AHIs differ significantly from US government control participants with respect to clinical, research, and biomarker assessments. Design, Setting, and Participants: Exploratory study conducted between June 2018 and July 2022 at the National Institutes of Health Clinical Center, involving 86 US government staff and family members with AHIs from Cuba, Austria, China, and other locations as well as 30 US government control participants. Exposures: AHIs. Main Outcomes and Measures: Participants were assessed with extensive clinical, auditory, vestibular, balance, visual, neuropsychological, and blood biomarkers (glial fibrillary acidic protein and neurofilament light) testing. The patients were analyzed based on the risk characteristics of the AHI identifying concerning cases as well as geographic location. Results: Eighty-six participants with AHIs (42 women and 44 men; mean [SD] age, 42.1 [9.1] years) and 30 vocationally matched government control participants (11 women and 19 men; mean [SD] age, 43.8 [10.1] years) were included in the analyses. Participants with AHIs were evaluated a median of 76 days (IQR, 30-537) from the most recent incident. In general, there were no significant differences between participants with AHIs and control participants in most tests of auditory, vestibular, cognitive, or visual function as well as levels of the blood biomarkers. Participants with AHIs had significantly increased fatigue, depression, posttraumatic stress, imbalance, and neurobehavioral symptoms compared with the control participants. There were no differences in these findings based on the risk characteristics of the incident or geographic location of the AHIs. Twenty-four patients (28%) with AHI presented with functional neurological disorders. Conclusions and Relevance: In this exploratory study, there were no significant differences between individuals reporting AHIs and matched control participants with respect to most clinical, research, and biomarker measures, except for objective and self-reported measures of imbalance and symptoms of fatigue, posttraumatic stress, and depression. This study did not replicate the findings of previous studies, although differences in the populations included and the timing of assessments limit direct comparisons. This study assesses whether participants with anomalous health incidents (AHIs) differ significantly from US government control participants with respect to clinical, research, and biomarker assessments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Common Oral Conditions: A Review.
- Author
-
Stoopler, Eric T., Villa, Alessandro, Bindakhil, Mohammed, Díaz, David L. Ojeda, and Sollecito, Thomas P.
- Subjects
THRUSH (Mouth disease) ,ORAL lichen planus ,CANKER sores ,XEROSTOMIA ,CELIAC disease ,FOLIC acid - Abstract
Importance: Dry mouth, oral candidiasis, and recurrent aphthous ulcers are 3 of the most common oral conditions that may be associated with patient discomfort, decreased quality of life, and morbidity. Observations: In a meta-analysis of 26 population-based cohort and cross-sectional studies, the global prevalence of dry mouth symptoms was 23% (95% CI, 18% to 28%), placing individuals at risk of oral candidiasis, dental caries, dysgeusia, masticatory/speech impairment, and oropharyngeal dysphagia. Dry mouth is associated with using more than 3 oral medications per day (odds ratio [OR], 2.9 [95% CI, 1.4 to 6.2]), head and neck radiation, and Sjögren disease. Symptoms may include difficulty swallowing and speaking, thirst, and halitosis. Dry mouth is associated with an 11.5% (95% CI, 3.6% to 27%) higher risk of oral candidiasis, based on a meta-analysis of 6 observational cohorts. Management of dry mouth includes mechanical salivary stimulants, oral moisturizers, and/or systemic sialagogues. Oral candidiasis is an opportunistic fungal infection caused by overgrowth of the Candida genus with C albicans, which accounts for 76.8% of infections. The prevalence of oral candidiasis is higher in patients who are immunosuppressed, for example, those with HIV (35% [95% CI, 28% to 42%]) and those with salivary gland hypofunction (OR, 3.02 [95% CI, 1.73 to 5.28]). Common risk factors associated with oral candidiasis include use of antibiotics (P =.04) and oral mucosal disorders such as lichen planus. Oral burning and dysgeusia are common symptoms of oral candidiasis. Treatment includes addressing risk factors and use of topical and/or systemic antifungal medications. Recurrent aphthous stomatitis is characterized by symptomatic round or oval oral ulcers, which are covered by a gray-white fibrin layer and encircled by an erythematous ring. A meta-analysis of 10 case-controlled studies revealed an increased risk of recurrent aphthous stomatitis associated with polymorphism of IL-1β (+3954C/T) (OR, 1.52 [95% CI, 1.07 to 2.17]) and IL-1β (−511C/T) (OR, 1.35 [95% CI, 1.09 to 1.67]). Another meta-analysis of 9 case-control studies reported that patients with recurrent aphthous stomatitis had a higher frequency of nutritional deficiencies, including vitamin B
12 (OR, 3.75 [95% CI, 2.38 to 5.94]), folic acid (OR, 7.55 [95% CI, 3.91 to 14.60]), and ferritin (OR, 2.62 [95% CI, 1.69 to 4.06]). Recurrent aphthous stomatitis can be associated with systemic diseases. A meta-analysis of 21 case-control studies revealed that celiac disease is associated with a higher incidence of recurrent aphthous stomatitis (25% vs 11%; OR, 3.79 [95% CI, 2.67 to 5.39]; P <.001). Topical corticosteroids are first-line agents to manage recurrent aphthous stomatitis; however, systemic medications may be necessary in more severe cases. Conclusions and Relevance: Dry mouth, oral candidiasis, and recurrent aphthous ulcers are common oral conditions that may be associated with patient discomfort, decreased quality of life, and morbidity. First-line treatment includes over-the-counter sialagogues for dry mouth, topical antifungals for oral candidiasis, and topical corticosteroids for aphthous ulcers. Oral conditions that do not improve with first-line treatment may require treatment with systemic medications. This review discusses diagnosis and first-line treatment options for dry mouth, oral candidiasis, and recurrent aphthous ulcers. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.
- Author
-
Yeh, Robert W., Shlofmitz, Richard, Moses, Jeffrey, Bachinsky, William, Dohad, Suhail, Rudick, Steven, Stoler, Robert, Jefferson, Brian K., Nicholson, William, Altman, John, Bateman, Cinthia, Krishnaswamy, Amar, Grantham, J. Aaron, Zidar, Frank J., Marso, Steven P., Tremmel, Jennifer A., Grines, Cindy, Ahmed, Mustafa I., Latib, Azeem, and Tehrani, Behnam
- Subjects
DRUG-eluting stents ,MYOCARDIAL infarction ,CORONARY restenosis ,PERCUTANEOUS coronary intervention ,CORONARY circulation ,CLINICAL trials ,REGULATORY approval - Abstract
Key Points: Question: Is treatment with a coronary paclitaxel-coated balloon superior to an uncoated balloon for 1-year target lesion failure in patients undergoing percutaneous coronary intervention for in-stent restenosis? Findings: In a multicenter randomized trial of 600 patients designed to support US regulatory approval, target lesion failure was significantly lower in the paclitaxel-coated balloon group (17.9%) compared with the uncoated balloon group (28.6%) (P =.003). Ischemia-driven target lesion revascularization and target vessel myocardial infarction were also lower after treatment with a paclitaxel-coated balloon. Meaning: Treatment with a paclitaxel-coated balloon offers an effective treatment strategy for the management of coronary in-stent restenosis. Importance: Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved for use in coronary circulation in the United States. Objective: To evaluate whether a paclitaxel-coated balloon is superior to an uncoated balloon in patients with in-stent restenosis undergoing percutaneous coronary intervention. Design, Setting, and Participants: AGENT IDE, a multicenter randomized clinical trial, enrolled 600 patients with in-stent restenosis (lesion length <26 mm and reference vessel diameter >2.0 mm to ≤4.0 mm) at 40 centers across the United States between May 2021 and August 2022. One-year clinical follow-up was completed on October 2, 2023. Interventions: Participants were randomized in a 2:1 allocation to undergo treatment with a paclitaxel-coated (n = 406) or an uncoated (n = 194) balloon. Main Outcomes and Measures: The primary end point of 1-year target lesion failure—defined as the composite of ischemia-driven target lesion revascularization, target vessel–related myocardial infarction, or cardiac death—was tested for superiority. Results: Among 600 randomized patients (mean age, 68 years; 157 females [26.2%]; 42 Black [7%], 35 Hispanic [6%] individuals), 574 (95.7%) completed 1-year follow-up. The primary end point at 1 year occurred in 17.9% in the paclitaxel-coated balloon group vs 28.6% in the uncoated balloon group, meeting the criteria for superiority (hazard ratio [HR], 0.59 [95% CI, 0.42-0.84]; 2-sided P =.003). Target lesion revascularization (13.0% vs 24.7%; HR, 0.50 [95% CI, 0.34-0.74]; P =.001) and target vessel–related myocardial infarction (5.8% vs 11.1%; HR, 0.51 [95% CI, 0.28-0.92]; P =.02) occurred less frequently among patients treated with paclitaxel-coated balloon. The rate of cardiac death was 2.9% vs 1.6% (HR, 1.75 [95% CI, 0.49-6.28]; P =.38) in the coated vs uncoated balloon groups, respectively. Conclusions and Relevance: Among patients undergoing coronary angioplasty for in-stent restenosis, a paclitaxel-coated balloon was superior to an uncoated balloon with respect to the composite end point of target lesion failure. Paclitaxel-coated balloons are an effective treatment option for patients with coronary in-stent restenosis. Trial Registration: ClinicalTrials.gov Identifier: NCT04647253 This clinical trial compares a paclitaxel-coated balloon vs an uncoated balloon in patients with in-stent restenosis undergoing percutaneous coronary intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
- Author
-
Marrazzo, Jeanne, Tao, Li, Becker, Marissa, Leech, Ashley A., Taylor, Allan W., Ussery, Faith, Kiragu, Michael, Reza-Paul, Sushena, Myers, Janet, Bekker, Linda-Gail, Yang, Juan, Carter, Christoph, de Boer, Melanie, Das, Moupali, Baeten, Jared M., and Celum, Connie
- Subjects
EMTRICITABINE-tenofovir ,HIV seroconversion ,HIV ,CISGENDER people - Abstract
Key Points: Question: What is the HIV incidence among cisgender women with different adherence trajectories to preexposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate? Findings: In this pooled analysis of 6296 participants from 11 postapproval studies of PrEP in cisgender women, the overall HIV incidence was 0.72 per 100 person-years. The HIV incidence rates per 100 person-years for different PrEP adherence trajectories were 0 for consistently daily (7 doses/week), 0.13 for consistently high (4-6 doses/week), 0.49 for high but declining (from a mean of 4-6 doses/week and then declining), and 1.27 for consistently low (less than 2 doses/week) adherence. Meaning: In a pooled analysis of postapproval studies, cisgender women with daily or consistently high adherence to emtricitabine and tenofovir disoproxil fumarate for PrEP experienced very low HIV incidence. Importance: Emtricitabine and tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP) is highly effective in cisgender men who have sex with men (MSM) when adherence is high (>4 doses/week). Real-world effectiveness and adherence with F/TDF for PrEP in cisgender women is less well characterized. Objective: To characterize the effectiveness of F/TDF for PrEP and its relationship with adherence in cisgender women. Design, Setting, and Participants: Data were pooled from 11 F/TDF PrEP postapproval studies conducted in 6 countries that included 6296 cisgender women aged 15 to 69 years conducted from 2012 to 2020. HIV incidence was evaluated according to adherence level measured objectively (tenofovir diphosphate concentration in dried blood spots or tenofovir concentration in plasma; n = 288) and subjectively (electronic pill cap monitoring, pill counts, self-report, and study-reported adherence scale; n = 2954) using group-based trajectory modeling. Exposures: F/TDF prescribed orally once a day. HIV incidence was analyzed in subgroups based on adherence trajectory. Main Outcomes and Measures: HIV incidence. Results: Of the 6296 participants, 46% were from Kenya, 28% were from South Africa, 21% were from India, 2.9% were from Uganda, 1.6% were from Botswana, and 0.8% were from the US. The mean (SD) age at PrEP initiation across all studies was 25 (7) years, with 61% of participants being younger than 25 years. The overall HIV incidence was 0.72 per 100 person-years (95% CI, 0.51-1.01; 32 incident HIV diagnoses among 6296 participants). Four distinct groups of adherence trajectories were identified: consistently daily (7 doses/week), consistently high (4-6 doses/week), high but declining (from a mean of 4-6 doses/week and then declining), and consistently low (less than 2 doses/week). None of the 498 women with consistently daily adherence acquired HIV. Only 1 of the 658 women with consistently high adherence acquired HIV (incidence rate, 0.13/100 person-years [95% CI, 0.02-0.92]). The incidence rate was 0.49 per 100 person-years (95% CI, 0.22-1.08) in the high but declining adherence group (n = 1166) and 1.27 per 100 person-years (95% CI, 0.53-3.04) in the consistently low adherence group (n = 632). Conclusions and Relevance: In a pooled analysis of 11 postapproval studies of F/TDF for PrEP among cisgender women, overall HIV incidence was 0.72 per 100 person-years; individuals with consistently daily or consistently high adherence (4-6 doses/week) to PrEP experienced very low HIV incidence. This pooled analysis of postapproval studies examines the association between baseline demographics and other characteristics and PrEP adherence trajectories with HIV incidence in women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Allergic Rhinitis: A Review.
- Author
-
Bernstein, Jonathan A., Bernstein, Joshua S., Makol, Richika, and Ward, Stephanie
- Subjects
ALLERGIC rhinitis ,ECZEMA ,SNEEZING ,NASAL mucosa ,EUSTACHIAN tube ,TENSION headache ,PATIENT preferences - Abstract
Importance: Allergic rhinitis affects an estimated 15% of the US population (approximately 50 million individuals) and is associated with the presence of asthma, eczema, chronic or recurrent sinusitis, cough, and both tension and migraine headaches. Observations: Allergic rhinitis occurs when disruption of the epithelial barrier allows allergens to penetrate the mucosal epithelium of nasal passages, inducing a T-helper type 2 inflammatory response and production of allergen-specific IgE. Allergic rhinitis typically presents with symptoms of nasal congestion, rhinorrhea, postnasal drainage, sneezing, and itching of the eyes, nose, and throat. In an international study, the most common symptoms of allergic rhinitis were rhinorrhea (90.38%) and nasal congestion (94.23%). Patients with nonallergic rhinitis present primarily with nasal congestion and postnasal drainage frequently associated with sinus pressure, ear plugging, muffled sounds and pain, and eustachian tube dysfunction that is less responsive to nasal corticosteroids. Patients with seasonal allergic rhinitis typically have physical examination findings of edematous and pale turbinates. Patients with perennial allergic rhinitis typically have erythematous and inflamed turbinates with serous secretions that appear similar to other forms of chronic rhinitis at physical examination. Patients with nonallergic rhinitis have negative test results for specific IgE aeroallergens. Intermittent allergic rhinitis is defined as symptoms occurring less than 4 consecutive days/week or less than 4 consecutive weeks/year. Persistent allergic rhinitis is defined as symptoms occurring more often than 4 consecutive days/week and for more than 4 consecutive weeks/year. Patients with allergic rhinitis should avoid inciting allergens. In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H
1 antihistamine (eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas patients with persistent moderate to severe allergic rhinitis should be treated initially with an intranasal corticosteroid (eg, fluticasone, triamcinolone, budesonide, mometasone) either alone or in combination with an intranasal antihistamine. In contrast, first-line therapy for patients with nonallergic rhinitis consists of an intranasal antihistamine as monotherapy or in combination with an intranasal corticosteroid. Conclusions and Relevance: Allergic rhinitis is associated with symptoms of nasal congestion, sneezing, and itching of the eyes, nose, and throat. Patients with allergic rhinitis should be instructed to avoid inciting allergens. Therapies include second-generation H1 antihistamines (eg, cetirizine, fexofenadine, desloratadine, loratadine), intranasal antihistamines (eg, azelastine, olopatadine), and intranasal corticosteroids (eg, fluticasone, triamcinolone, budesonide, mometasone) and should be selected based on the severity and frequency of symptoms and patient preference. This narrative review discusses the pathogenesis, differential diagnosis, treatments, and prognosis for patients with allergic rhinitis. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Adolescent Δ8-THC and Marijuana Use in the US.
- Author
-
Harlow, Alyssa F., Miech, Richard A., and Leventhal, Adam M.
- Subjects
MARIJUANA legalization ,ELECTRONIC cigarettes ,MARIJUANA ,TEENAGERS ,RACE ,DRUGGED driving - Abstract
Key Points: Question: What is the prevalence of self-reported Δ
8 -tetrahydrocannabinol (THC) and marijuana use among 12th-grade students in the US and its distribution across sociodemographic factors and state cannabis policies? Findings: In this nationally representative 2023 survey, 11.4% of 2186 US 12th-grade students self-reported Δ8 -THC use and 30.4% self-reported marijuana use in the past year. Δ8 -THC use prevalence was higher in the South and Midwest US and in states without legal adult-use marijuana or Δ8 -THC regulations. Marijuana use prevalence did not differ by cannabis policies. Meaning: Δ8 -THC use prevalence is appreciable among US adolescents and is a potential public health concern. Importance: Gummies, flavored vaping devices, and other cannabis products containing psychoactive hemp-derived Δ8 -tetrahydrocannabinol (THC) are increasingly marketed in the US with claims of being federally legal and comparable to marijuana. National data on prevalence and correlates of Δ8 -THC use and comparisons to marijuana use among adolescents in the US are lacking. Objective: To estimate the self-reported prevalence of and sociodemographic and policy factors associated with Δ8 -THC and marijuana use among US adolescents in the past 12 months. Design, Setting, and Participants: This nationally representative cross-sectional analysis included a randomly selected subset of 12th-grade students in 27 US states who participated in the Monitoring the Future Study in-school survey during February to June 2023. Exposures: Self-reported sex, race, ethnicity, and parental education; census region; state-level adult-use (ie, recreational) marijuana legalization (yes vs no); and state-level Δ8 -THC policies (regulated vs not regulated). Main Outcomes and Measures: The primary outcome was self-reported Δ8 -THC and marijuana use in the past 12 months (any vs no use and number of occasions used). Results: In the sample of 2186 12th-grade students (mean age, 17.7 years; 1054 [48.9% weighted] were female; 232 [11.1%] were Black, 411 [23.5%] were Hispanic, 1113 [46.1%] were White, and 328 [14.2%] were multiracial), prevalence of self-reported use in the past 12 months was 11.4% (95% CI, 8.6%-14.2%) for Δ8 -THC and 30.4% (95% CI, 26.5%-34.4%) for marijuana. Of those 295 participants reporting Δ8 -THC use, 35.4% used it at least 10 times in the past 12 months. Prevalence of Δ8 -THC use was lower in Western vs Southern census regions (5.0% vs 14.3%; risk difference [RD], −9.4% [95% CI, −15.2% to −3.5%]; adjusted risk ratio [aRR], 0.35 [95% CI, 0.16-0.77]), states in which Δ8 -THC was regulated vs not regulated (5.7% vs 14.4%; RD, −8.6% [95% CI, −12.9% to −4.4%]; aRR, 0.42 [95% CI, 0.23-0.74]), and states with vs without legal adult-use marijuana (8.0% vs 14.0%; RD, −6.0% [95% CI, −10.8% to −1.2%]; aRR, 0.56 [95% CI, 0.35-0.91]). Use in the past 12 months was lower among Hispanic than White participants for Δ8 -THC (7.3% vs 14.4%; RD, −7.2% [95% CI, −12.2% to −2.1%]; aRR, 0.54 [95% CI, 0.34-0.87]) and marijuana (24.5% vs 33.0%; RD, −8.5% [95% CI, −14.9% to −2.1%]; aRR, 0.74 [95% CI, 0.59-0.94]). Δ8 -THC and marijuana use prevalence did not differ by sex or parental education. Conclusions and Relevance: Δ8 -THC use prevalence is appreciable among US adolescents and is higher in states without marijuana legalization or existing Δ8 -THC regulations. Prioritizing surveillance, policy, and public health efforts addressing adolescent Δ8 -THC use may be warranted. This cross-sectional nationally representative classroom-based survey of US 12th-grade students examines the self-reported prevalence of and sociodemographic and policy factors associated with Δ8 -THC and marijuana use during a 12-month period. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
18. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
- Author
-
Ruberg, Frederick L. and Maurer, Mathew S.
- Subjects
CARDIAC amyloidosis ,TRANSTHYRETIN ,IMMUNOGLOBULIN light chains ,ATRIAL arrhythmias ,CARRIER proteins ,SYMPTOMS - Abstract
Importance: Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy. Observations: Transthyretin (TTR) protein transports thyroxine (thyroid hormone) and retinol (vitamin A) and is synthesized predominantly by the liver. When the TTR protein misfolds, it can form amyloid fibrils that deposit in the heart causing heart failure, heart conduction block, or arrhythmia such as atrial fibrillation. The biological processes by which amyloid fibrils form are incompletely understood but are associated with aging and, in some patients, affected by inherited variants in the TTR genetic sequence. ATTR amyloidosis results from misfolded TTR protein deposition. ATTR can occur in association with normal TTR genetic sequence (wild-type ATTR) or with abnormal TTR genetic sequence (variant ATTR). Wild-type ATTR primarily manifests as cardiomyopathy while ATTR due to a genetic variant manifests as cardiomyopathy and/or polyneuropathy. Approximately 50 000 to 150 000 people in the US have heart failure due to ATTR amyloidosis. Without treatment, heart failure due to ATTR amyloidosis is associated with a median survival of approximately 5 years. More than 130 different inherited genetic variants in TTR exist. The most common genetic variant is Val122Ile (pV142I), an allele with an origin in West African countries, that is present in 3.4% of African American individuals in the US or approximately 1.5 million persons. The diagnosis can be made using serum free light chain assay and immunofixation electrophoresis to exclude light chain amyloidosis combined with cardiac nuclear scintigraphy to detect radiotracer uptake in a pattern consistent with amyloidosis. Loop diuretics, such as furosemide, torsemide, and bumetanide, are the primary treatment for fluid overload and symptomatic relief of patients with ATTR heart failure. An ATTR-directed therapy that inhibited misfolding of the TTR protein (tafamidis, a protein stabilizer), compared with placebo, reduced mortality from 42.9% to 29.5%, reduced hospitalizations from 0.7/year to 0.48/year, and was most effective when administered early in disease course. Conclusions and Relevance: ATTR amyloidosis causes cardiomyopathy in up to approximately 150 000 people in the US and tafamidis is the only currently approved therapy. Tafamidis slowed progression of ATTR amyloidosis and improved survival and prevented hospitalization, compared with placebo, in people with ATTR-associated cardiomyopathy. This Review summarizes the clinical presentation, diagnosis, and treatment of amyloidosis from transthyretin (ATTR) protein cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Changes in Health Care Workers' Economic Outcomes Following Medicaid Expansion.
- Author
-
Matta, Sasmira, Chatterjee, Paula, and Venkataramani, Atheendar S.
- Subjects
MEDICAL personnel ,MEDICAID ,EMPLOYER-sponsored health insurance ,HEALTH equity ,AMERICAN Community Survey ,SOCIOECONOMIC disparities in health - Abstract
Key Points: Question: Do health care workers benefit from improved health sector finances? Findings: In this difference-in-differences study, only health care workers in higher-earning occupations (eg, registered nurses, physicians, and managers) experienced increases in annual income after state-level Medicaid expansion, which has been shown to improve health care organization finances. Health care workers in lower-earning occupations (eg, health aides, attendants, service staff) were more likely to report coverage under the Medicaid program after expansion and less likely to hold employer–sponsored health insurance. Meaning: Improved health care organization finances may increase inequality in the health care workforce, with implications for compounding structural inequalities within the industry and worker and patient health and well-being. Importance: The extent to which changes in health sector finances impact economic outcomes among health care workers, especially lower-income workers, is not well known. Objective: To assess the association between state adoption of the Affordable Care Act's Medicaid expansion—which led to substantial improvements in health care organization finances—and health care workers' annual incomes and benefits, and whether these associations varied across low- and high-wage occupations. Design, Setting, and Participants: Difference-in-differences analysis to assess differential changes in health care workers' economic outcomes before and after Medicaid expansion among workers in 30 states that expanded Medicaid relative to workers in 16 states that did not, by examining US individuals aged 18 through 65 years employed in the health care industry surveyed in the 2010-2019 American Community Surveys. Exposure: Time-varying state-level adoption of Medicaid expansion. Main Outcomes and Measures: Primary outcome was annual earned income; secondary outcomes included receipt of employer–sponsored health insurance, Medicaid, and Supplemental Nutrition Assistance Program benefits. Results: The sample included 1 322 263 health care workers from 2010-2019. Health care workers in expansion states were similar to those in nonexpansion states in age, sex, and educational attainment, but those in expansion states were less likely to identify as non-Hispanic Black. Medicaid expansion was associated with a 2.16% increase in annual incomes (95% CI, 0.66%-3.65%; P =.005). This effect was driven by significant increases in annual incomes among the top 2 highest-earning quintiles (β coefficient, 2.91%-3.72%), which includes registered nurses, physicians, and executives. Health care workers in lower-earning quintiles did not experience any significant changes. Medicaid expansion was associated with a 3.15 percentage point increase in the likelihood that a health care worker received Medicaid benefits (95% CI, 2.46 to 3.84; P <.001), with the largest increases among the 2 lowest-earning quintiles, which includes health aides, orderlies, and sanitation workers. There were significant decreases in employer–sponsored health insurance and increases in SNAP following Medicaid expansion. Conclusion and Relevance: Medicaid expansion was associated with increases in compensation for health care workers, but only among the highest earners. These findings suggest that improvements in health care sector finances may increase economic inequality among health care workers, with implications for worker health and well-being. This study examines the difference in health care worker compensation between states that expanded and those that did not expand Medicaid after the passage of the Affordable Care Act. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Diagnosis and Management of Paroxysmal Supraventricular Tachycardia.
- Author
-
Peng, Gary and Zei, Paul C.
- Subjects
SUPRAVENTRICULAR tachycardia ,CHILD patients ,DIAGNOSIS ,CATHETER ablation ,SYMPTOM burden ,ATRIOVENTRICULAR node - Abstract
Importance: Paroxysmal supraventricular tachycardia (PSVT), defined as tachyarrhythmias that originate from or conduct through the atria or atrioventricular node with abrupt onset, affects 168 to 332 per 100 000 individuals. Untreated PSVT is associated with adverse outcomes including high symptom burden and tachycardia-mediated cardiomyopathy. Observations: Approximately 50% of patients with PSVT are aged 45 to 64 years and 67.5% are female. Most common symptoms include palpitations (86%), chest discomfort (47%), and dyspnea (38%). Patients may rarely develop tachycardia-mediated cardiomyopathy (1%) due to PSVT. Diagnosis is made on electrocardiogram during an arrhythmic event or using ambulatory monitoring. First-line acute therapy for hemodynamically stable patients includes vagal maneuvers such as the modified Valsalva maneuver (43% effective) and intravenous adenosine (91% effective). Emergent cardioversion is recommended for patients who are hemodynamically unstable. Catheter ablation is safe, highly effective, and recommended as first-line therapy to prevent recurrence of PSVT. Meta-analysis of observational studies shows single catheter ablation procedure success rates of 94.3% to 98.5%. Evidence is limited for the effectiveness of long-term pharmacotherapy to prevent PSVT. Nonetheless, guidelines recommend therapies including calcium channel blockers, β-blockers, and antiarrhythmic agents as management options. Conclusion and Relevance: Paroxysmal SVT affects both adult and pediatric populations and is generally a benign condition. Catheter ablation is the most effective therapy to prevent recurrent PSVT. Pharmacotherapy is an important component of acute and long-term management of PSVT. This Review summarizes current evidence regarding the diagnosis and treatment of paroxysmal supraventricular tachycardia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Neurodevelopmental Outcomes of Extremely Preterm Infants Fed Donor Milk or Preterm Infant Formula: A Randomized Clinical Trial.
- Author
-
Colaizy, Tarah T., Poindexter, Brenda B., McDonald, Scott A., Bell, Edward F., Carlo, Waldemar A., Carlson, Susan J., DeMauro, Sara B., Kennedy, Kathleen A., Nelin, Leif D., Sánchez, Pablo J., Vohr, Betty R., Johnson, Karen J., Herron, Dianne E., Das, Abhik, Crawford, Margaret M., Walsh, Michele C., Higgins, Rosemary D., Stoll, Barbara J., Ambalavanan, Namisavayam, and Wyckoff, Myra H.
- Subjects
PREMATURE infants ,BABY foods ,INFANT formulas ,CLINICAL trials ,BREAST milk ,NEURAL development ,DELAY of gratification ,CRYING - Abstract
Key Points: Question: Among extremely preterm infants fed minimal maternal milk, does feeding of donor human milk compared with preterm formula during the birth hospitalization result in improved neurodevelopmental outcomes? Findings: In this randomized clinical trial, the Bayley Scales of Infant and Toddler Development adjusted mean cognitive score was 80.7 (measured at 22-26 months' corrected age) for infants fed donor human milk vs 81.1 for infants fed preterm formula (adjusted between-group mean difference, −0.77 [95% CI, −3.93 to 2.39]), which was not a significant difference. The adjusted mean language and motor scores also did not differ. Meaning: Among extremely preterm infants, donor milk feeding did not result in different 2-year neurodevelopmental outcomes compared with preterm formula feeding. Importance: Maternal milk feeding of extremely preterm infants during the birth hospitalization has been associated with better neurodevelopmental outcomes compared with preterm formula. For infants receiving no or minimal maternal milk, it is unknown whether donor human milk conveys similar neurodevelopmental advantages vs preterm formula. Objective: To determine if nutrient-fortified, pasteurized donor human milk improves neurodevelopmental outcomes at 22 to 26 months' corrected age compared with preterm infant formula among extremely preterm infants who received minimal maternal milk. Design, Setting, and Participants: Double-blind, randomized clinical trial conducted at 15 US academic medical centers within the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Infants younger than 29 weeks 0 days' gestation or with a birth weight of less than 1000 g were enrolled between September 2012 and March 2019. Intervention: Preterm formula or donor human milk feeding from randomization to 120 days of age, death, or hospital discharge. Main Outcomes and Measures: The primary outcome was the Bayley Scales of Infant and Toddler Development (BSID) cognitive score measured at 22 to 26 months' corrected age; a score of 54 (score range, 54-155; a score of ≥85 indicates no neurodevelopmental delay) was assigned to infants who died between randomization and 22 to 26 months' corrected age. The 24 secondary outcomes included BSID language and motor scores, in-hospital growth, necrotizing enterocolitis, and death. Results: Of 1965 eligible infants, 483 were randomized (239 in the donor milk group and 244 in the preterm formula group); the median gestational age was 26 weeks (IQR, 25-27 weeks), the median birth weight was 840 g (IQR, 676-986 g), and 52% were female. The birthing parent's race was self-reported as Black for 52% (247/478), White for 43% (206/478), and other for 5% (25/478). There were 54 infants who died prior to follow-up; 88% (376/429) of survivors were assessed at 22 to 26 months' corrected age. The adjusted mean BSID cognitive score was 80.7 (SD, 17.4) for the donor milk group vs 81.1 (SD, 16.7) for the preterm formula group (adjusted mean difference, −0.77 [95% CI, −3.93 to 2.39], which was not significant); the adjusted mean BSID language and motor scores also did not differ. Mortality (death prior to follow-up) was 13% (29/231) in the donor milk group vs 11% (25/233) in the preterm formula group (adjusted risk difference, −1% [95% CI, −4% to 2%]). Necrotizing enterocolitis occurred in 4.2% of infants (10/239) in the donor milk group vs 9.0% of infants (22/244) in the preterm formula group (adjusted risk difference, −5% [95% CI, −9% to −2%]). Weight gain was slower in the donor milk group (22.3 g/kg/d [95% CI, 21.3 to 23.3 g/kg/d]) compared with the preterm formula group (24.6 g/kg/d [95% CI, 23.6 to 25.6 g/kg/d]). Conclusions and Relevance: Among extremely preterm neonates fed minimal maternal milk, neurodevelopmental outcomes at 22 to 26 months' corrected age did not differ between infants fed donor milk or preterm formula. Trial Registration: ClinicalTrials.gov Identifier: NCT01534481 This randomized clinical trial compares the effect of donor human milk on neurodevelopmental outcomes at 22 to 26 months' corrected age compared with preterm infant formula among extremely preterm infants who received minimal maternal milk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.
- Author
-
Kamel, Hooman, Longstreth Jr, W. T., Tirschwell, David L., Kronmal, Richard A., Marshall, Randolph S., Broderick, Joseph P., Aragón García, Rebeca, Plummer, Pamela, Sabagha, Noor, Pauls, Qi, Cassarly, Christy, Dillon, Catherine R., Di Tullio, Marco R., Hod, Eldad A., Soliman, Elsayed Z., Gladstone, David J., Healey, Jeff S., Sharma, Mukul, Chaturvedi, Seemant, and Janis, L. Scott
- Subjects
ISCHEMIC stroke ,P-waves (Electrocardiography) ,STROKE patients ,BRAIN natriuretic factor ,INTRACRANIAL hemorrhage ,APIXABAN ,ATRIAL flutter - Abstract
Key Points: Question: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy? Findings: In this randomized clinical trial that included 1015 patients, the rate of recurrent stroke did not significantly differ between the apixaban group (annualized rate, 4.4%) and the aspirin group (annualized rate, 4.4%). Meaning: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Importance: Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation. Objective: To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. Design, Setting, and Participants: Multicenter, double-blind, phase 3 randomized clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, defined as P-wave terminal force greater than 5000 μV × ms in electrocardiogram lead V
1 , serum N-terminal pro-B-type natriuretic peptide level greater than 250 pg/mL, or left atrial diameter index of 3 cm/m2 or greater on echocardiogram. Participants had no evidence of atrial fibrillation at the time of randomization. Enrollment and follow-up occurred from February 1, 2018, through February 28, 2023, at 185 sites in the National Institutes of Health StrokeNet and the Canadian Stroke Consortium. Interventions: Apixaban, 5 mg or 2.5 mg, twice daily (n = 507) vs aspirin, 81 mg, once daily (n = 508). Main Outcomes and Measures: The primary efficacy outcome in a time-to-event analysis was recurrent stroke. All participants, including those diagnosed with atrial fibrillation after randomization, were analyzed according to the groups to which they were randomized. The primary safety outcomes were symptomatic intracranial hemorrhage and other major hemorrhage. Results: With 1015 of the target 1100 participants enrolled and mean follow-up of 1.8 years, the trial was stopped for futility after a planned interim analysis. The mean (SD) age of participants was 68.0 (11.0) years, 54.3% were female, and 87.5% completed the full duration of follow-up. Recurrent stroke occurred in 40 patients in the apixaban group (annualized rate, 4.4%) and 40 patients in the aspirin group (annualized rate, 4.4%) (hazard ratio, 1.00 [95% CI, 0.64-1.55]). Symptomatic intracranial hemorrhage occurred in 0 patients taking apixaban and 7 patients taking aspirin (annualized rate, 1.1%). Other major hemorrhages occurred in 5 patients taking apixaban (annualized rate, 0.7%) and 5 patients taking aspirin (annualized rate, 0.8%) (hazard ratio, 1.02 [95% CI, 0.29-3.52]). Conclusions and Relevance: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Trial Registration: ClinicalTrials.gov Identifier: NCT03192215 This clinical trial compares the effectiveness of anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
23. Examining Excess Mortality Associated With the COVID-19 Pandemic for Renters Threatened With Eviction.
- Author
-
Graetz, Nick, Hepburn, Peter, Gershenson, Carl, Porter, Sonya R., Sandler, Danielle H., Lemmerman, Emily, and Desmond, Matthew
- Subjects
COVID-19 pandemic ,EVICTION ,HOUSING stability ,RACE ,AGE groups - Abstract
Key Points: Question: What were the patterns of excess mortality associated with the COVID-19 pandemic among renters who received eviction filings? Findings: In this retrospective study of 282 000 renters who received an eviction filing between January 1, 2020, and August 31, 2021, an excess mortality analysis found that observed mortality was 106% higher than expected. By comparison, observed mortality among similar renters was 25% higher than expected and among the general population was 9% higher than expected. Meaning: Housing instability, as measured by eviction filings, was associated with significantly increased risk of death over the first 20 months of the COVID-19 pandemic. Eviction prevention efforts may have reduced excess mortality for renters during this period. Importance: Residential evictions may have increased excess mortality associated with the COVID-19 pandemic. Objective: To estimate excess mortality associated with the COVID-19 pandemic for renters who received eviction filings (threatened renters). Design, Setting, and Participants: This retrospective cohort study used an excess mortality framework. Mortality based on linked eviction and death records from 2020 through 2021 was compared with projected mortality estimated from similar records from 2010 through 2016. Data from court records between January 1, 2020, and August 31, 2021, were collected via the Eviction Lab's Eviction Tracking System. Similar data from court records between January 1, 2010, and December 31, 2016, also collected by the Eviction Lab, were used to estimate projected mortality during the pandemic. We also constructed 2 comparison groups: all individuals living in the study area and a subsample of those individuals living in high-poverty, high-filing tracts. Exposures: Eviction filing. Main Outcomes and Measures: All-cause mortality in a given month. The difference between observed mortality and projected mortality was used as a measure of excess mortality associated with the pandemic. Results: The cohort of threatened renters during the pandemic period consisted of 282 000 individuals (median age, 36 years [IQR, 28-47]). Eviction filings were 44.7% lower than expected during the study period. The composition of threatened renters by race, ethnicity, sex, and socioeconomic characteristics during the pandemic was comparable with the prepandemic composition. Expected cumulative age-standardized mortality among threatened renters during this 20-month period of the pandemic was 116.5 (95% CI, 104.0-130.3) per 100 000 person-months, and observed mortality was 238.6 (95% CI, 230.8-246.3) per 100 000 person-months or 106% higher than expected. In contrast, expected mortality for the population living in similar neighborhoods was 114.6 (95% CI, 112.1-116.8) per 100 000 person-months, and observed mortality was 142.8 (95% CI, 140.2-145.3) per 100 000 person-months or 25% higher than expected. In the general population across the study area, expected mortality was 83.5 (95% CI, 83.3-83.8) per 100 000 person-months, and observed mortality was 91.6 (95% CI, 91.4-91.8) per 100 000 person-months or 9% higher than expected. The pandemic produced positive excess mortality ratios across all age groups among threatened renters. Conclusions and Relevance: Renters who received eviction filings experienced substantial excess mortality associated with the COVID-19 pandemic. This cohort study of renters who received eviction filings, similar renters who did not, and the general population across the study area compares rates of excess mortality associated with the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Paxlovid Is Effective but Underused—Here's What the Latest Research Says About Rebound and More.
- Author
-
Rubin, Rita
- Subjects
COVID-19 treatment ,COVID-19 - Abstract
This Medical News story examines the latest information about rebound, treatment eligibility, optimal dosing, and other questions related to nirmatrelvir-ritonavir for treating COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Management of Food Allergies and Food-Related Anaphylaxis.
- Author
-
Iglesia, Edward G. A., Kwan, Mildred, Virkud, Yamini V., and Iweala, Onyinye I.
- Subjects
FOOD allergy ,PEANUT allergy ,ANAPHYLAXIS ,SYMPTOMS ,ALLERGENS ,ALLERGIES - Abstract
Importance: An estimated 7.6% of children and 10.8% of adults have IgE-mediated food-protein allergies in the US. IgE-mediated food allergies may cause anaphylaxis and death. A delayed, IgE-mediated allergic response to the food-carbohydrate galactose-α-1,3-galactose (alpha-gal) in mammalian meat affects an estimated 96 000 to 450 000 individuals in the US and is currently a leading cause of food-related anaphylaxis in adults. Observations: In the US, 9 foods account for more than 90% of IgE-mediated food allergies—crustacean shellfish, dairy, peanut, tree nuts, fin fish, egg, wheat, soy, and sesame. Peanut is the leading food-related cause of fatal and near-fatal anaphylaxis in the US, followed by tree nuts and shellfish. The fatality rate from anaphylaxis due to food in the US is estimated to be 0.04 per million per year. Alpha-gal syndrome, which is associated with tick bites, is a rising cause of IgE-mediated food anaphylaxis. The seroprevalence of sensitization to alpha-gal ranges from 20% to 31% in the southeastern US. Self-injectable epinephrine is the first-line treatment for food-related anaphylaxis. The cornerstone of IgE-food allergy management is avoidance of the culprit food allergen. There are emerging immunotherapies to desensitize to one or more foods, with one current US Food and Drug Administration–approved oral immunotherapy product for treatment of peanut allergy. Conclusions and Relevance: IgE-mediated food allergies, including delayed IgE-mediated allergic responses to red meat in alpha-gal syndrome, are common in the US, and may cause anaphylaxis and rarely, death. IgE-mediated anaphylaxis to food requires prompt treatment with epinephrine injection. Both food-protein allergy and alpha-gal syndrome management require avoiding allergenic foods, whereas alpha-gal syndrome also requires avoiding tick bites. This clinical review summarizes the epidemiology, pathophysiology, clinical presentation, prevention, diagnosis, and management of IgE-mediated food allergy and anaphylaxis to food proteins and food glycans. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. "Scalable Privilege"—How AI Could Turn Data From the Best Medical Systems Into Better Care for All.
- Author
-
Anderer, Samantha and Hswen, Yulin
- Subjects
ARTIFICIAL intelligence ,PHYSICIANS - Abstract
This Medical News article is an interview with JAMA Editor in Chief Kirsten Bibbins-Domingo and physician Atul Butte, the University of California Health System's chief data scientist. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Thyroid Cancer: A Review.
- Author
-
Boucai, Laura, Zafereo, Mark, and Cabanillas, Maria E.
- Subjects
THYROID cancer ,ANAPLASTIC thyroid cancer ,MEDULLARY thyroid carcinoma ,IODINE isotopes ,LYMPHATIC metastasis ,GENETIC mutation - Abstract
Importance: Approximately 43 720 new cases of thyroid carcinoma are expected to be diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. Observations: Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, follicular (≈4%), and oncocytic (≈2%) forms arise from thyroid follicular cells and are termed well-differentiated thyroid cancer. Aggressive forms of follicular cell-derived thyroid cancer are poorly differentiated thyroid cancer (≈5%) and anaplastic thyroid cancer (≈1%). Medullary thyroid cancer (≈4%) arises from parafollicular C cells. Most cases of well-differentiated thyroid cancer are asymptomatic and detected during physical examination or incidentally found on diagnostic imaging studies. For microcarcinomas (≤1 cm), observation without surgical resection can be considered. For tumors larger than 1 cm with or without lymph node metastases, surgery with or without radioactive iodine is curative in most cases. Surgical resection is the preferred approach for patients with recurrent locoregional disease. For metastatic disease, surgical resection or stereotactic body irradiation is favored over systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, cabozantinib) are approved for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%. Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. Conclusions: Approximately 44 000 new cases of thyroid cancer are diagnosed each year in the US, with a 5-year relative survival of 98.5%. Surgery is curative in most cases of well-differentiated thyroid cancer. Radioactive iodine treatment after surgery improves overall survival in patients at high risk of recurrence. Antiangiogenic multikinase inhibitors and targeted therapies to genetic mutations that give rise to thyroid cancer are increasingly used in the treatment of metastatic disease. This narrative review summarizes current evidence regarding the pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Age-Related Macular Degeneration: A Review.
- Author
-
Fleckenstein, Monika, Schmitz-Valckenberg, Steffen, and Chakravarthy, Usha
- Subjects
MACULAR degeneration ,ENDOTHELIAL growth factors ,VISION disorders ,OPTICAL coherence tomography ,DIETARY supplements ,POLYPOIDAL choroidal vasculopathy ,PUPIL diseases - Abstract
Importance: Age-related macular degeneration (AMD) affects approximately 20 million people in the US and 196 million people worldwide. AMD is a leading cause of severe vision impairment in older people and is expected to affect approximately 288 million people worldwide by 2040. Observations: Older age, genetic factors, and environmental factors, such as cigarette smoking, are associated with development of AMD. AMD occurs when extracellular deposits accumulate in the outer retina, ultimately leading to photoreceptor degeneration and loss of central vision. The late stages of AMD are characterized by outer retinal atrophy, termed geographic atrophy, or neovascularization associated with subretinal and/or intraretinal exudation, termed exudative neovascular AMD. The annual incidence of AMD ranges from 0.3 per 1000 in people who are aged 55 to 59 years to 36.7 per 1000 in people aged 90 years or older. The estimated heritability of late-stage AMD is approximately 71% (95% CI, 18%-88%). Long-term prospective cohort studies show a significantly higher AMD incidence in people who smoke more than 20 cigarettes per day compared with people who never smoked. AMD is diagnosed primarily with clinical examination that includes a special lens that focuses light of the slit lamp through the pupil. Exudative neovascular AMD is best identified using angiography and by optical coherence tomography. Individuals with AMD who take nutritional supplements consisting of high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability to progress to late-stage AMD at 5 years vs a 28% probability for those taking a placebo. In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti–vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment. Conclusions and Relevance: The prevalence of AMD is anticipated to increase worldwide to 288 million individuals by 2040. Intravitreally administered anti-VEGF treatment is first-line therapy for exudative neovascular AMD. This review summarizes current evidence regarding pathophysiology, risk factors, clinical presentation, diagnosis, and treatment of age-related macular degeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Will Generative Artificial Intelligence Deliver on Its Promise in Health Care?
- Author
-
Wachter, Robert M. and Brynjolfsson, Erik
- Subjects
ARTIFICIAL intelligence ,MEDICAL quality control ,INFORMATION technology ,DIGITAL technology ,MEDICAL care - Abstract
Generative artificial intelligence (AI) has been touted as a potential innovation for greater diagnostic accuracy and clinical efficiency in health care, but whether generative AI will deliver on this promise or fall to the "productivity paradox" is examined in this Special Communication. Importance: Since the introduction of ChatGPT in late 2022, generative artificial intelligence (genAI) has elicited enormous enthusiasm and serious concerns. Observations: History has shown that general purpose technologies often fail to deliver their promised benefits for many years ("the productivity paradox of information technology"). Health care has several attributes that make the successful deployment of new technologies even more difficult than in other industries; these have challenged prior efforts to implement AI and electronic health records. However, genAI has unique properties that may shorten the usual lag between implementation and productivity and/or quality gains in health care. Moreover, the health care ecosystem has evolved to make it more receptive to genAI, and many health care organizations are poised to implement the complementary innovations in culture, leadership, workforce, and workflow often needed for digital innovations to flourish. Conclusions and Relevance: The ability of genAI to rapidly improve and the capacity of organizations to implement complementary innovations that allow IT tools to reach their potential are more advanced than in the past; thus, genAI is capable of delivering meaningful improvements in health care more rapidly than was the case with previous technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Will Generative AI Tools Improve Access to Reliable Health Information?
- Author
-
Anderer, Samantha and Hswen, Yulin
- Subjects
GENERATIVE artificial intelligence ,COMMUNICABLE diseases ,WORLD health ,PUBLIC universities & colleges ,PUBLIC health - Abstract
This Medical News article is an interview with JAMA Editor in Chief Kirsten Bibbins-Domingo and Virologist Davey Smith, head of the Division of Infectious Diseases and Global Public Health at the University of California, San Diego. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Digital Avatars and Personalized Voices—How AI Is Helping to Restore Speech to Patients.
- Author
-
Anderer, Samantha and Hswen, Yulin
- Subjects
SPEECH ,ARTIFICIAL intelligence ,AVATARS (Virtual reality) ,NEUROSCIENCES ,APHASIA - Abstract
In this Medical News article, Edward Chang, MD, chair of the department of neurological surgery at the University of California, San Francisco Weill Institute for Neurosciences joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the potential for AI to revolutionize communication for those unable to speak due to aphasia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. NIH Study Provides Long-Awaited Insight Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
- Author
-
Eastman, Quinn
- Subjects
CHRONIC fatigue syndrome - Abstract
This Medical News article discusses a new US National Institutes of Health study of patients with the chronic—and chronically misunderstood—disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. How Machine Learning Might Help Improve Cardiac Imaging.
- Author
-
Anderer, Samantha and Hswen, Yulin
- Subjects
CARDIAC imaging ,MACHINE learning ,MEDICAL history taking ,CARDIOLOGISTS ,ARTIFICIAL intelligence - Abstract
In this Medical News interview, University of California, San Francisco, cardiologist Rima Arnaout, joins JAMA Editor in Chief Kirsten Bibbins-Domingo to discuss the transformative potential of AI on cardiac imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs.
- Author
-
Suran, Melissa
- Subjects
HALLUCINOGENIC drugs - Abstract
This Medical News article discusses a recent study that examined the remedies most often recommended on Reddit for diluting psychedelic experiences. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. AI Developers Should Understand the Risks of Deploying Their Clinical Tools, MIT Expert Says.
- Author
-
Anderer, Samantha and Hswen, Yulin
- Subjects
ARTIFICIAL intelligence ,MACHINE learning ,TECHNICAL institutes ,MEDICAL care - Abstract
This Medical News article is an interview with Marzyeh Ghassemi, a machine learning expert at the Massachusetts Institute of Technology who focuses on health care applications, and JAMA Editor in Chief Kirsten Bibbins-Domingo. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Mental Health Symptoms When Abortion Access Is Restricted.
- Author
-
Steinberg, Julia R.
- Subjects
MENTAL illness ,ABORTION ,ROE v. Wade - Abstract
The article discusses the broader implications of overturning Roe v Wade in June 2022, highlighting concerns beyond abortion statistics, such as maternal and infant mortality. Topics include the potential mental health repercussions of restrictive abortion policies, a study's findings on increased anxiety and depression symptoms in trigger-ban states post-Dobbs, and the importance of clinicians' awareness in states with abortion restrictions.
- Published
- 2024
- Full Text
- View/download PDF
37. Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID.
- Author
-
Suran, Melissa
- Subjects
POST-acute COVID-19 syndrome ,COVID-19 treatment ,ANTIVIRAL agents ,SCIENTIFIC observation ,SARS-CoV-2 - Abstract
This Medical News article discusses 2 new observational studies that examined associations with SARS-CoV-2 antiviral medications and long COVID. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. On the Other Side.
- Author
-
Bohjanen, Sara
- Subjects
HEREDITARY nonpolyposis colorectal cancer ,NARRATIVE medicine ,CANCER treatment ,EMOTIONS - Abstract
In this narrative medicine essay, a medical student participating in a study learns she has Lynch syndrome, setting off a cascade of emotions of dread, fear, and some hope in diagnostic plans and future breakthroughs in cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. A Patient With Oral Discomfort and Reduced Oral Aperture.
- Author
-
Chen, Gloria F., Roy, Simon F., and Cohen, Jeffrey M.
- Subjects
SMOKELESS tobacco ,ORAL mucosa ,BETEL nut ,SMOKING ,TOBACCO use - Abstract
A patient had burning and pain in the mouth, reduced oral aperture, white-tan plaques on the oral mucosa, and thickened buccal mucosae bilaterally; biopsy of the lower labial mucosa showed subepithelial fibrosis. She had no history of cigarette smoking or use of chewing tobacco but had current and past history of chewing areca nuts. What is the diagnosis and what would you do next? [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. When It Comes to SARS-CoV-2 Clearance, People Who Are Immunocompromised Are Not All Alike.
- Author
-
Rubin, Rita
- Subjects
SARS-CoV-2 - Abstract
This Medical News story discusses a recent study that found people who are immunocompromised clear SARS-CoV-2 at varying rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults.
- Author
-
Chen, Dayu, Ren, Haozhen, and Zhao, Yuanjin
- Subjects
CEFEPIME ,ADULTS ,KNEE pain - Published
- 2024
- Full Text
- View/download PDF
42. Fever, Rash, and Shortness of Breath in a 69-Year-Old.
- Author
-
Tiwari, Vivekanand and Miller, Alexander T.
- Subjects
DYSPNEA ,FEVER ,PULMONARY nodules ,TESTING laboratories ,LEUCOPENIA - Abstract
A 69-year-old had fever, fatigue, rash, right periorbital swelling, and shortness of breath. Chest computed tomography revealed numerous small, bilateral pulmonary nodules; laboratory testing revealed mean corpuscular volume, 96.1 fL; hemoglobin level, 12.4 mg/dL; and leukopenia. What is the diagnosis and what would you do next? [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Social Media Industry Standards Needed to Protect Adolescent Mental Health, Says National Academies.
- Author
-
Anderer, Samantha
- Subjects
SOCIAL media ,MASS media industry ,ADOLESCENT health ,MENTAL health - Abstract
This Medical News article discusses new recommendations to maximize the benefits and minimize the harms of the social media platforms, including suggestions for research and clinician training. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. An Incarcerated Individual With Weight Loss and Interstitial Pulmonary Infiltrates.
- Author
-
Kapoor, Nilesh, Dietz, Christina, and Buettner, Benjamin P.
- Subjects
PRISONERS ,SYNCOPE ,COMPUTED tomography ,HYPOXEMIA ,SARS-CoV-2 - Abstract
A man with HIV had syncopal episodes and hypoxemia after recent exposure to SARS-CoV-2; computed tomography revealed diffuse bilateral pulmonary micronodular opacities, a 2.2-cm nodule in the lingula, and mediastinal and hilar lymphadenopathy. What is the diagnosis and what would you do next? [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Why Stating Hypotheses in Grant Applications Is Unnecessary.
- Author
-
Hernán, Miguel A. and Greenland, Sander
- Subjects
GOVERNMENT aid - Abstract
This Viewpoint argues that a hypothesis-centric approach to writing grant applications is problematic and instead suggests that funding applications should be evaluated by their relevance and methodological quality rather than by qualitative assertions before the study is conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Progressive Dyspnea on Exertion in an 82-Year-Old.
- Author
-
Mathavan, Akshay, Mathavan, Akash, and Ataya, Ali
- Subjects
HEREDITARY hemorrhagic telangiectasia ,DYSPNEA ,HEART murmurs ,OLDER patients ,PULMONARY embolism - Abstract
An older patient with hereditary hemorrhagic telangiectasia and right lower lobe segmental pulmonary embolism presented with dyspnea that had worsened over 5 years; physical examination and laboratory testing showed jugular venous distension, a cardiac systolic murmur, right ventricular heave, bilateral lower extremity edema to the knees, and elevated brain-type natriuretic peptide level. What is the diagnosis and what would you do next? [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Nostrums*.
- Subjects
SCIENTIFIC knowledge ,HUMAN behavior - Abstract
The article focuses on the prevalence and implications of non-standard medicines, particularly proprietary or secret remedies, in the U.S. during the late nineteenth century. It discusses the shift from pharmacy being viewed as a profession to becoming more of a business, raises concerns about the efficacy and safety of these unregulated medications, and addresses the involvement of medical professionals in promoting such products.
- Published
- 2024
- Full Text
- View/download PDF
48. Safe Viewing of Solar Eclipses.
- Author
-
Bressler, Neil M., Kong, Jun, and Arévalo, J. Fernando
- Subjects
SOLAR eclipses - Abstract
This JAMA Patient Page describes solar eclipses and how to view them safely. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Foreign Letters.
- Subjects
PROHIBITION, United States, 1920-1933 ,OCCUPATIONAL diseases - Abstract
The article offers news briefs related to events and societal issues in various locations, including a sword duel between hospital surgeons in Paris and insights into the Prohibition Movement in Belgium.
- Published
- 2024
- Full Text
- View/download PDF
50. Brain Work.
- Subjects
ACID-base equilibrium ,BRAIN metabolism ,MEDICAL periodicals - Abstract
The article discusses the relationship between exercise, mental activity, and metabolism, tracing back to Lavoisier's observation that exercise increases oxygen consumption. It explores how various forms of bodily and mental activities are associated with chemical changes and energy expenditure, highlighting the role of basal metabolism and the need for food to replace expended energy.
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.